Novel biologics in inflammatory bowel disease

Georgios I Papachristou; Scott Plevy

doi:10.1016/j.gtc.2004.02.007

Novel biologics in inflammatory bowel disease

Gastroenterol Clin North Am. 2004 Jun;33(2):251-69, ix. doi: 10.1016/j.gtc.2004.02.007.

Authors

Georgios I Papachristou¹, Scott Plevy

Affiliation

¹ Division of Gastroenterology, Hepatology and Nutrition, The University of Pittsburgh School of Medicine, Scaife Hall, Room 566, 3550 Terrace Street, Pittsburgh, PA 15261, USA.

PMID: 15177537
DOI: 10.1016/j.gtc.2004.02.007

Abstract

Understanding of immunologic mechanisms involved in the initiation and perpetuation of chronic inflammation has led to new therapeutic opportunities in the inflammatory bowel diseases. The term "biologics" is used to distinguish new biotechnologic therapeutics from the conventional drugs used in the treatment of immune-mediated inflammatory disorders. This article reviews novel biologic therapies that are being investigated for the treatment of Crohn's disease and ulcerative colitis.

Publication types

Review

MeSH terms

Adalimumab
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Certolizumab Pegol
Humans
Immunoglobulin Fab Fragments
Immunosuppressive Agents / therapeutic use*
Inflammatory Bowel Diseases / drug therapy*
Infliximab
Polyethylene Glycols / therapeutic use

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Immunoglobulin Fab Fragments
Immunosuppressive Agents
CDP 571
Polyethylene Glycols
Infliximab
Adalimumab
Certolizumab Pegol